{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:54:32Z","timestamp":1767034472775,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15332-0","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:42:30Z","timestamp":1767033750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between antihypertensive drugs and cancer risk: evidence from a population-based study in the Abruzzo region, Southern Italy"],"prefix":"10.1186","volume":"25","author":[{"given":"Annalisa","family":"Marotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Vicenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Odio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"15332_CR1","unstructured":"World Health O. Global report on hypertension: the race against a silent killer. 2023, Geneva: World Health Organization."},{"issue":"11","key":"15332_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, et al. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802.","journal-title":"Nat Rev Cardiol"},{"key":"15332_CR3","doi-asserted-by":"publisher","unstructured":"Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2025 Apr 7;46(14):1300. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf031. Erratum for: Eur Heart J. 2024 Oct 7;45(38):3912-4018.","DOI":"10.1093\/eurheartj\/ehaf031"},{"issue":"37","key":"15332_CR4","doi-asserted-by":"publisher","first-page":"62545","DOI":"10.18632\/oncotarget.19117","volume":"8","author":"H Ni","year":"2017","unstructured":"Ni H, et al. Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8(37):62545\u201360.","journal-title":"Oncotarget"},{"issue":"6","key":"15332_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/joim.12446","volume":"278","author":"DA Butt","year":"2015","unstructured":"Butt DA, Harvey PJ. Benefits and risks of antihypertensive medications in the elderly. J Intern Med. 2015;278(6):599\u2013626.","journal-title":"J Intern Med"},{"issue":"3","key":"15332_CR6","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15332_CR7","doi-asserted-by":"publisher","first-page":"8565","DOI":"10.1038\/s41598-019-45014-4","volume":"9","author":"A Seretis","year":"2019","unstructured":"Seretis A, et al. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019;9(1):8565.","journal-title":"Sci Rep"},{"issue":"4","key":"15332_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.14740\/jocmr3744","volume":"11","author":"D Shin","year":"2019","unstructured":"Shin D, et al. Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies. J Clin Med Res. 2019;11(4):247\u201355.","journal-title":"J Clin Med Res"},{"issue":"1","key":"15332_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-022-02419-9","volume":"20","author":"SC Shao","year":"2022","unstructured":"Shao SC, et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med. 2022;20(1):228.","journal-title":"BMC Med"},{"issue":"15","key":"15332_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","volume":"22","author":"E Grossman","year":"2001","unstructured":"Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J. 2001;22(15):1343\u201352.","journal-title":"Eur Heart J"},{"issue":"4","key":"15332_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1185\/03007995.2013.772505","volume":"29","author":"M Monami","year":"2013","unstructured":"Monami M, et al. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin. 2013;29(4):369\u201378.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"15332_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/157488607780598296","volume":"2","author":"G Corrao","year":"2007","unstructured":"Corrao G, et al. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf. 2007;2(2):125\u201333.","journal-title":"Curr Drug Saf"},{"issue":"6","key":"15332_CR13","first-page":"801","volume":"33","author":"J Qi","year":"2022","unstructured":"Qi J, et al. Anti-hypertensive medications and risk of colorectal cancer: a systematic review and meta-analysis. Cancer Causes Control. 2022;33(6):801\u201312.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"15332_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12020-013-9973-3","volume":"45","author":"K Esposito","year":"2014","unstructured":"Esposito K, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28\u201336.","journal-title":"Endocrine"},{"key":"15332_CR15","doi-asserted-by":"publisher","first-page":"44877","DOI":"10.1038\/srep44877","volume":"7","author":"H Han","year":"2017","unstructured":"Han H, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7:44877.","journal-title":"Sci Rep"},{"key":"15332_CR16","doi-asserted-by":"publisher","first-page":"31358","DOI":"10.1038\/srep31358","volume":"6","author":"Z Liang","year":"2016","unstructured":"Liang Z, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.","journal-title":"Sci Rep"},{"issue":"5","key":"15332_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41416-023-02544-z","volume":"130","author":"MP Little","year":"2024","unstructured":"Little MP, et al. Minimum latency effects for cancer associated with exposures to radiation or other carcinogens. Br J Cancer. 2024;130(5):819\u201329.","journal-title":"Br J Cancer"},{"key":"15332_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9010060","author":"S Hollingworth","year":"2021","unstructured":"Hollingworth S, Kairuz T. Measuring medicine use: applying ATC\/DDD methodology to real-world data. Pharmacy (Basel). 2021. https:\/\/doi.org\/10.3390\/pharmacy9010060.","journal-title":"Pharmacy (Basel)"},{"issue":"12","key":"15332_CR19","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1097\/HJH.0000000000003841","volume":"42","author":"M Franchi","year":"2024","unstructured":"Franchi M, et al. Long-term exposure to antihypertensive drugs and the risk of cancer occurrence: evidence from a large population-based study. J Hypertens. 2024;42(12):2107\u201314.","journal-title":"J Hypertens"},{"key":"15332_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040771","author":"IJ Cho","year":"2021","unstructured":"Cho IJ, et al. Antihypertensive drugs and the risk of cancer: a nationwide cohort study. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10040771.","journal-title":"J Clin Med"},{"issue":"4","key":"15332_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1470-2045(21)00033-4","volume":"22","author":"E Copland","year":"2021","unstructured":"Copland E, et al. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol. 2021;22(4):558\u201370.","journal-title":"Lancet Oncol"},{"key":"15332_CR22","doi-asserted-by":"crossref","unstructured":"Strom BL, Kimmel SE and Hennessy S. Pharmacoepidemiology. 5th ed. 2012, Chichester, West Sussex, UK: Wiley-Blackwell. xxi, 953 p.","DOI":"10.1002\/9781119959946"},{"issue":"6","key":"15332_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.0000222373.59104.3d","volume":"47","author":"MT Halpern","year":"2006","unstructured":"Halpern MT, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039\u201348.","journal-title":"Hypertension"},{"issue":"35","key":"15332_CR24","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1093\/eurheartj\/ehab899","volume":"43","author":"G Corrao","year":"2022","unstructured":"Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022;43(35):3312\u201322.","journal-title":"Eur Heart J"},{"issue":"1","key":"15332_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12885-023-10849-8","volume":"23","author":"S Wang","year":"2023","unstructured":"Wang S, et al. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai. BMC Cancer. 2023;23(1):425.","journal-title":"BMC Cancer"},{"key":"15332_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2697","volume":"344","author":"K Bhaskaran","year":"2012","unstructured":"Bhaskaran K, et al. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK general practice research database. BMJ. 2012;344:e2697.","journal-title":"BMJ"},{"issue":"1","key":"15332_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-022-06528-0","volume":"193","author":"OW Scott","year":"2022","unstructured":"Scott OW, et al. Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat. 2022;193(1):225\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"15332_CR28","doi-asserted-by":"crossref","unstructured":"Arbuckle L, Ritchie F, The five safes of risk-based anonymization. 2019.","DOI":"10.1109\/MSEC.2019.2929282"},{"key":"15332_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191911876","author":"P Zhang","year":"2022","unstructured":"Zhang P, Kamel Boulos MN. Privacy-by-design environments for large-scale health research and federated learning from data. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph191911876.","journal-title":"Int J Environ Res Public Health"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15332-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:42:31Z","timestamp":1767033751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15332-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15332"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15332-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors complied with the ethical standards of the relevant national and institutional committee on human experimentation and with the Declaration of Helsinki of 1975, as revised in 2013. The study was approved by the institutional review board of the Department of Medical, Oral and Biotechnological Sciences, of the University \u2018G. d\u2019 Annunzio\u2019 of Chieti-Pescara (Chieti, Italy) and data security was ensured by the pseudo-anonymization of identification codes from regional healthcare databases. No patients were personally identifiable at any time during the entire study period. Privacy-by-design (or data protection-by-design) principles were adopted in this study [\n                      \n                      ].According to the rules from the Italian Medicines Agency retrospective studies without direct contact with patients do not need a written consent to process personal data when they are used for research aims. However, a more comprehensive overview of \u2018privacy research by design\u2019 can be found in existing literature [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1902"}}